Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of tobramycin inhalation powder in non-cystic fibrosis bronchiectasis with Pseudomonas aeruginosa infection
NL-OMON47708Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tobramycin in bronchiectasis and Pseudomonas aeruginosa airway infection, sponsored by Novartis. Primary endpoint: Change in Pseudomonas aeruginosa sputum bacterial load from baseline to Day 29. Planned start Jan 2017; status: withdrawn.
02
Drugs
tobramycin
03
Conditions
bronchiectasisPseudomonas aeruginosa airway infection
Beyond the preview
Go deeper on NL-OMON47708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47708.